|
US2019274984A1
|
|
Polymorphic forms of sodium benzoate and uses thereof
|
|
US2020331894A1
|
|
D-amino acid oxidase inhibitors and therapeutic uses thereof
|
|
US2020085792A1
|
|
Formulations of cycloserine compounds and applications thereof
|
|
US10485790B1
|
|
Salts of cycloserine compounds and applications thereof
|
|
US2019367549A1
|
|
Inhibitors of D-amino acid oxidase (DAAO) and uses thereof
|
|
US2018228753A1
|
|
Co-crystals of substituted glycine and uses thereof
|
|
TW201924669A
|
|
Improved enrichment methods for preparing tannic acid compositions
|
|
KR20200097255A
|
|
Improved enrichment method for preparing tannic acid compositions
|
|
US10098861B1
|
|
Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
|
|
US2019112289A1
|
|
D-amino acid oxidase inhibitors and therapeutic uses thereof
|
|
TW201823223A
|
|
Co-crystal and/or eutectic crystal of kojic acid, compositions comprising the same, process of producing the same, and uses thereof
|
|
US2018036267A1
|
|
Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
|
|
US2019008813A1
|
|
Lithium salts of N-substituted glycine compounds and uses thereof
|
|
TW201828934A
|
|
Compositions containing tannic acids and uses thereof
|
|
KR20190018477A
|
|
Co-crystals of sodium benzoate and uses thereof
|
|
TWI626043B
|
|
Use of Lithium Benzoate for Treating Central Nervous System Disorders
|
|
MX2018015463A
|
|
Co-crystals of lithium benzoate and uses thereof.
|
|
KR20190017940A
|
|
Use of lithium benzoate to treat central nervous system disorders
|
|
KR20190005157A
|
|
Compositions Containing Tannic Acid and Uses Thereof
|
|
US2018111891A1
|
|
Polymorphic forms of sodium benzoate and uses thereof
|
